| scholarly article | Q13442814 |
| P356 | DOI | 10.3899/JRHEUM.081324 |
| P698 | PubMed publication ID | 19797507 |
| P50 | author | Min-Chan Park | Q56670159 |
| P2093 | author name string | Ja Kyung Kim | |
| Yong-Beom Park | |||
| Soo-Kon Lee | |||
| Soo-Jin Chung | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis B | Q6853 |
| P304 | page(s) | 2416-2420 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | The Journal of Rheumatology | Q7743623 |
| P1476 | title | Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy | |
| P478 | volume | 36 |
| Q36154001 | A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier |
| Q40243616 | A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha |
| Q42809793 | A study of TNF-alpha-238 and -308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China |
| Q37970447 | Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management |
| Q45325449 | Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study |
| Q35779755 | Biologic response modifiers to decrease inflammation: Focus on infection risks. |
| Q35237588 | Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective |
| Q40471375 | Clinical characteristics of adverse events associated with therapeutic monoclonal antibodies in Korea. |
| Q55287694 | Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections. |
| Q38239127 | HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. |
| Q38755178 | Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions |
| Q28076703 | Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened |
| Q91706568 | Hepatitis B Virus Reactivation in the Setting of Immunosuppressive Drug Therapy |
| Q26784247 | Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations |
| Q38155954 | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs |
| Q44688947 | Hepatitis B virus reactivation in a juvenile rheumatoid arthritis patient under treatment and its successful management: a complicated case |
| Q45359495 | Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases |
| Q37655919 | Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review |
| Q89970158 | Incidence of hepatitis B virus infection among human immunodeficiency virus-infected treatment naïve adults in Botswana |
| Q36153966 | KASL Clinical Practice Guidelines: Management of chronic hepatitis B. |
| Q64897844 | KASL clinical practice guidelines for management of chronic hepatitis B. |
| Q26752475 | KASL clinical practice guidelines: management of chronic hepatitis B |
| Q38084250 | Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases |
| Q46733182 | Les modificateurs de la réponse biologique pour réduire l’inflammation : pleins feux sur les risques d’infection |
| Q36328982 | Occult Hepatitis B (OBH) in Clinical Settings |
| Q36676348 | Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis |
| Q37296502 | Prevalence of hepatitis B and C infections in rheumatoid arthritis and ankylosing spondylitis: A multicenter countrywide study |
| Q42531427 | Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines? |
| Q89511736 | Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases |
| Q38630548 | Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. |
| Q45369749 | Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts |
| Q38810735 | Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders |
| Q37862588 | Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy |
| Q90608529 | Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations |
| Q37812847 | Rheumatologic Disease and the Liver |
| Q38611674 | Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): a Systematic Review and Meta-analysis |
| Q35237316 | Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. |
| Q37766276 | Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature |
| Q43035871 | Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases |
| Q38411930 | Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists |
| Q38099248 | Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies |
| Q64913856 | Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. |
| Q37894193 | TNF alpha antagonist therapy and safety monitoring |
| Q44390967 | The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis |
| Q41750745 | The long-term effects of anti-TNF-α agents on patients with chronic viral hepatitis C and B infections |
| Q92434527 | Therapeutic management with biological anti-TNF-α agent in severe psoriasis associated with chronic hepatitis B: A case report |
| Q28084305 | Treatment of rheumatic diseases and hepatitis B virus coinfection |
| Q47546977 | Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice |
| Q34620375 | Update of the management of chronic psoriasis: new approaches and emerging treatment options. |
| Q44464843 | Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. |
| Q37879197 | Viral arthritides |
| Q82719630 | [Infectious complications of biologic therapy in patients with rheumatoid arthritis] |
Search more.